Skip to main content

Table 3 Summary of pharmacokinetic similarity analysis in Study 1 and Study 2

From: Comparison of two biosimilarity studies of FKB327 with the adalimumab reference product: randomized phase 1 studies of single-blind, single-dose subcutaneous injection in healthy Japanese male participants

 

Ratio of geometric LS mean (90% CI)

Study 1

Study 2

FKB327 / RP

FKB327 / RP

Parameters

ANOVA

ANCOVAa

ANOVA

ANCOVAa

Cmax

1.07 (0.99, 1.16)

1.06 (0.99, 1.13)

1.05 (1.00, 1.11)

1.05 (1.01, 1.10)

AUC0-t

1.17 (1.05, 1.30)b

1.15 (1.04, 1.28) b

1.11 (1.01, 1.23)

1.12 (1.01, 1.23)

AUC0-∞

1.16 (1.03, 1.31) b

1.16 (1.04, 1.29) b

1.11 (0.99, 1.24)

1.12 (1.00, 1.25)b

AUC0–360

1.10 (1.01, 1.19)

1.08 (1.01, 1.16)

1.04 (0.98, 1.10)

1.04 (0.99, 1.10)

T1/2

1.14 (0.97, 1.35)b

1.14 (0.97, 1.34)b

1.02 (0.86, 1.22)

1.02 (0.85, 1.22)

  1. aANCOVA: Body weight and age in both Study 1 and Study 2, and site added in Study 2 as covariates
  2. bData did not meet prespecified equivalence criteria of 0.80 to 1.25
  3. ANCOVA Analysis of covariance; ANOVA Analysis of variance; AUC0-∞ Area under the concentration-time curve from time zero to infinity; AUC0–360 Area under the concentration-time curve from time zero to 360 h; AUC0-t Area under the concentration-time curve from time zero to the last measurable concentration; Cmax Maximum serum concentration; RP Reference product; T1/2 Half-life